In the Gray Market, the Premium (GMP) is currently approximately 4% above the upper price band of RS 91, which indicates a modest listing premium. The company offers a new issue of 1.33 shares of Crore shares, with a price band between RS 86 and RS 91 per share.
Anlon Healthcare GMP today
The IPO of Anlon Healthcare is traded with a premium of 4.4% in the gray market and exceeds its upper price band of RS 91, which suggests a modest profit prior to the offer. This means that the problem is likely to be mentioned in the neighborhood of RS 95.GMP Note: The Gray Market Premium (GMP) represents the unofficial premium investors who are willing to pay prior to the official list of the shares.
Anlon Healthcare subscription status
The issue was completely subscribed to day 1. On the second day so far, the problem has been applied 1.84 times. Retail individual investors (Riis) led the question and subscribed 10.34 times the 13.30 Lakh shares that have been reserved for them. Non-institutional investors (NIIs) subscribed to 79% of their 19.95 LAKH stock quota, while qualified institutional buyers (QIBS) read bids for 91% of the shares of 99.75 LAKH that were assigned to them.
Anlon Healthcare IPO -Details
The RS 121 Crore IPO from Anlon Healthcare is open for subscription on 26 August and will remain open until August 29. The issue consists of a new range of 1.33 equity shares, with a price band from RS 86 to RS 91 per share.
The minimum party size is 164 shares, for which a retail investment of approximately RS 14,924 is required. Interactive Financial Services manages the problem, while KFIN Technologies acted as a registrar. The shares are planned to mention on 3 September on the NSE SME platform.
Company background
Anlon Healthcare, located in Rajkot, Gujarat, is a chemical production company focused on producing pharmaceutical intermediates with high purity and active pharmaceutical ingredients (APIs). The products serve as important raw materials for the formulation of tablets, capsules, ointments, nutraceuticals, articles for personal care and veterinary APIs.
The company is one of the few domestic producers of Loxoprofen sodium dihydrate-a commonly used anti-inflammatory medication for arthritis, back pain and post-surgical recovery. Anlon has submitted several drugmaster files (DMFs) to international markets, including the EU, Russia, Japan and South Korea, and active approval with the American FDA.
The product portfolio comprises more than 65 commercialized products, in addition to 28 in the pilot phase and 49 under laboratory tests.
In FY25, Anlon Healthcare reported the turnover of RS 120 Crore, a sharp rise in RS 66 Crore in FY24. The net profit is also more than doubled and rises to RS 20.5 Crore from RS 9.7 Crore in the previous year.
Use of IPO yield
The yield of the IPO is used to expand the production capacities, to repay selected loans and to meet general business requirements.
Should investors consider subscribing?
Brokerage company Anand Rathi has assigned a “subscribe – long -term” rating to the IPO of Anlon Healthcare, referring to its strong and diversified product portfolio, scalable business model and approvals of the regulations in multiple geographies.
However, the company notes that the IPO is ‘completely priced’, with a 19x p/e ratio based on FY25 income and an EV/EBITDA of 16.7x. As such, it mainly recommends the issue for investors with a long -term horizon.
Identified important risks include strict supervision of regulations, potential closing installations and exposure to audits for product quality, which can lead to delays or cancellations.
((Indemnification: Recommendations, suggestions, views and opinions of the experts are their own. These do not represent the views of economic times)
#Anlon #Healthcare #IPO #edition #applied #day #GMP #subscribe